3.4702.36% ( +0.080 )
Delay Closed: Nov 16, 16:08:00Profile
About

BIODLINK-B
01875.HK
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. In addition, the company develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD).
Profile
- Company Name
- BioDlink International Company Limited
- Market
- SEHK
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- biodlink.com
Related Securities
Industry
Industry RankingsValueRank
Management
NamePosition
